Frontline BioVentures
VC Fund
Shanghai, China
Frontline BioVentures is a VC fund in Shanghai focused on Health Care and Biotechnology. ###Frontline BioVentures merged with WuXi Healthcare Ventures to form 6 Dimensions Capital###Frontline BioVentures is a premier China-based venture capital firm specialize in the investment of innovative life science companiesWe focus on business within strategic life science and technology areas promoted by the Chinese government.Currentlywe manage two funds, a RMB denominated fund and a parallel USD fund, which offers structural flexibilities to best serve the needs of portfolio companies.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 24%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Frontline BioVentures invests in
Stages Frontline BioVentures invests in
Countries Frontline BioVentures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 8 (47%)
- Biotechnology 6 (35%)
- Medical 4 (24%)
- Pharmaceutical 4 (24%)
- Manufacturing 3 (18%)
Stage
- Venture - Series Unknown 5 (29%)
- Series B 4 (24%)
- Series C 3 (18%)
- Series A 2 (12%)
- Series D 1 (6%)
Country
- China 12 (71%)
- United States 3 (18%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Lianyong Chen
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Yikon Genomics is a leading solution-based single cell sequencing company. Currently based on the patented MALBAC® technology from Harvard University, Yikon provides complete solutions in the fields of reproductive health and cancer diagnostics with liquid tumor biopsy. The MALBAC-PGS™ and MALBAC-PGD™ solutions offer the most accurate andcomprehensive embryo testing results for physicians to choose the best embryos with balanced chromosomal copy numbers,without inheriting the known disease-associated alleles. The MALBAC-PGS™ and MALBAC-PGD™ solutions have helped thousands of couples to achieve successful pregnancies. Yikon will continue to interpret the code of life and bring people the hope and joy of life. | $38.7M / Series D / May 06, 2021 | ||
| Guoke Hengtai (Beijing) Medical Technology Co., Ltd. was established in February 2013 and is affiliated to Oriental Science and Technology Holding Group Co., Ltd. (hereinafter referred to as “Oriental Instrument”), a subsidiary of the State-owned Assets Supervision and Administration Commission of the Chinese Academy of Sciences. It isheadquartered in Yizhuang Economic and Technological Development Zone, Beijing. . Since the establishment of Guoke Hengtai for 4 years, the company has experienced two rounds of investment in A and B, and its performance has continued to grow at a high speed, with a compound annual growth rate of over 50%. In 2017, the company officially launched the IPO listing journey. | $154.5M / Series C / Sep 09, 2019 | ||
| Sinopharm Online has a pharmaceutical retail platform to provide users with online medication consultation, medical and health management consulting services, etc. The main sales cover Chinese and Western medicines and health products. , medical equipment, Chinese medicine | $44.6M / Series B / Apr 26, 2019 | ||
| Shenzhen Dano Pharmaceuticals specializes in the development, manufacturing and marketing of pharmaceutical API. | Venture - Series Unknown / Jan 01, 2019 | ||
| Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and willeventually be valuable for clinical diagnostic use. It was founded in 2015 and headquartered in Cambridge, Massachusetts. | $20M / Series B / Jan 23, 2018 | ||
| Yidebang is a Beijing-based healthcare software developer, which provides management solution, drug supply, hierarchical diagnosis and treatment and other supporting medical services for basic-level clinics in China. | $9M / Series A / Nov 09, 2017 | ||
Cutagen
|
Cutagen is a Operator of a specialty medical device company focused on advanced wound and skin care for clinical use and cosmetic applications. The company's products provide a local hyperoxic environment to facilitate the healing and management of injured tissues of skin or oral mucosa and the improvement in the appearance of skin. | Venture - Series Unknown / Jan 01, 2017 | |
| TenNor Therapeutics is a clinical stage, product development company with a sharp focus on unmet medical needs in the area of infectious diseases. The company possesses a dual-acting drug discovery platform with several innovative products in various stages of preclinical and clinical development. The company is developing new drugs for thetreatment of Helicobacter pylori infections, prosthetic joint infections, multidrug-resistant Gram-negative infections and some other common and serious infectious diseases. | $25M / Series B / Sep 19, 2016 | ||
| Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXiVentures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action. | $50M / Series C / Apr 21, 2016 | ||
| Coherent Biopharma is a pahrmaceutical based agency. | $8M / Series A / Feb 01, 2016 | ||
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Frontline BioVentures invest in?
Frontline BioVentures invests primarily in Health Care, Biotechnology and Medical startups, most often at Venture - Series Unknown and Series B stage. Most of the 17 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Frontline BioVentures?
Public channels for Frontline BioVentures include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Frontline BioVentures?
The team at Frontline BioVentures includes Lianyong Chen (Founder and Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
